As of 2025-12-19, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -6.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 91.52 mil USD. OCX's TTM EBITDA according to its financial statements is -14.41 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 15.1x | 14.9x |
| Forward P/E multiples | 19.2x - 34.6x | 21.7x |
| Fair Price | (9.67) - (7.59) | (9.22) |
| Upside | -402.1% - -337.2% | -388.2% |
| Date | EV/EBITDA |